Audicin Seeking €300k Investments (€30k Already Committed)

Copyright: Audicin Oy, 2023

At a Glance

Audio medicine company Audicin helps you recharge while you work. We are developing a digital therapeutics (DTx) for the treatment and prevention of work related acute stress, including the state of high exhaustion and burnout. Our clients include: S-Group (the biggest private sector employer in Finland), LeadSpark, Fonecta and Franklin Foods (in the USA).

Traction and Ask

With €27k net revenues and €8k profit in 2022, and a €2.2M pre-money valuation, Audicin is looking to raise €300k pre-seed funding and gain B2B SaaS, and healthtech expertise from investors. The investment is needed to:

  1. To grow the revenue by 60% by the end of 2H/2023
  2. To develop and launch Audicin DTx compliant app in the beginning of 2H/2023
  3. To start business in the USA in the beginning of 2H/2023

Market, Business Model, Financials and Team

In a global workplace stress management market worth $9,26Bn (+11,4% CARG/Year), Audicin was founded in 2022 in Helsinki, Finland. Audicin is monetizing mainly through B2B and B2C monthly subscriptions charged to large enterprises, channel partners such as car manufacturers, airlines, wearable providers and individual buyers. Revenue growth is projected at 3x YoY (breakeven in 2025), reaching €1.3M by Q4 2025. Audicin team of 4 (3 co-founders and 1 employee) combines 40+ years of commercial, audio medicine and technology expertise. 

Competitive Advantage

Key USPs versus competitors like Calm, Headspace, Endel and HealthTunes are: a) Audicin enables people to recharge while they work – no breaks, breathing exercises or other effort is needed, b) Audicin is building MDR / FDA approved audio medicine, forcing the non MDR / FDA compliant players out from the market and c) Audicin is the only one with progress measurement, tracking and treatment personalization. 

Round Details

Audicin has previously raised €15k in grants from Google to develop its first version of the MVP, it has been pre-selected to VITA Accelerator and has received a term sheet for €150k investmentment (€90k in cash) from them. 

We aim to close this pre-seed round by 15.5.2023, with some minority investors already committed to join with €30k (plus an additional €30k in soft commitments). €10k is the minimum investment ticket size.

Get in Touch

Laura Avonius (Founder, CEO) and the other founders are speaking with potential investors over the next few weeks and are keen to pitch, demo and open up their traction and financial plans in detail.

Get in touch with us to find out more.